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Synthesis, in vitro, and in vivo
evaluation of novel
N‑phenylindazolyl diarylureas
as potential anti‑cancer agents
Lucas N. Solano1, Grady L. Nelson1, Conor T. Ronayne1, Shirisha Jonnalagadda1,
Sravan K. Jonnalagadda1, Kaija Kottke2, Robert Chitren3, Joseph L. Johnson2,5,
Manoj K. Pandey4, Subash C. Jonnalagadda3 & Venkatram R. Mereddy1,2,5*
Novel N-phenylindazole based diarylureas have been designed, synthesized and evaluated as
potential anticancer agents. In vitro cell viability studies of these derivatives illustrate good potency
with IC50 values in the range of 0.4–50 μM in several cancer cell lines including murine metastatic
breast cancer 4T1, murine glioblastoma GL261, human triple negative breast cancer MDA-MB-231,
human pancreatic cancer MIAPaCa-2, and human colorectal cancer cell line WiDr. The ester group in
the lead compound 8i was modified to incorporate amino-amides to increase solubility and stability
while retaining biological activity. Further in vitro studies reveal that lead candidates inhibit tube
length in HUVEC cells. In vivo systemic toxicity studies indicate that these candidate compounds are
well tolerated in mice without any significant side effects. Anticancer efficacy studies in WiDr tumor
xenograft and 4T1 tumor syngraft models demonstrate that the lead candidate 11 exhibits significant
antitumor properties as a single agent in these tumor models.
Nitrogen‐containing heterocycles are pharmacologically important scaffolds and are present in numerous clinically approved drugs1–3. Nitrogenous heterocycles offer a unique opportunity in drug development as they readily allow for the manipulation of lipophilicity, polarity, and hydrogen bonding1–3. These manipulations could
potentially result in improved physiochemical properties including pharmacokinetics, pharmacodynamics, and
toxicological profile to enhance efficacy of drugs1–3. Indazoles are a class of nitrogen-containing heterocycles
related to the naturally found indoles, are comprised of a benzene fused to a pyrazole and can exist as 1H‐indazole, 2H‐indazole, and 3H‐indazole. Indazoles have been extensively studied for their pharmaceutical properties
and have been shown to have high compatibility for drug development4–6. Literature reports indicate that the
indazole structural unit is utilized in numerous pharmacologically active agents including drugs with anti-cancer
properties4–6. For example, indazole-based pazopanib and axitinib have been developed as multi-tyrosine kinase
inhibitors that are clinically indicated for the treatment of a variety of c ancers7–16.
Ureas are carbonyl groups flanked by two nitrogens which have unique hydrogen bonding capabilities and as
a result, they are frequently included in the drug design and discovery process17. Diaryl ureas have recently been
explored as pharmacophores for the development of anticancer agents with numerous mechanisms of action,
including anti-angiogenesis17. Examples of diaryl urea containing anticancer agents include regorafenib and
sorafenib with clinical indications for colorectal and kidney cancers, r espectively18–23.
Owing to the importance of indazoles and diaryl ureas in drug development, we envisioned that conjugating indazole template with diphenyl urea would provide an opportunity to design novel drug candidates with
angiogenesis inhibition properties (Fig. 1). In the current work, we have synthesized and evaluated a series of
N-phenylindazolyl diarylureas derivatives as potential anticancer agents.

1

Integrated Biosciences Graduate Program, University of Minnesota, Duluth, MN 55812, USA. 2Department
of Chemistry and Biochemistry, University of Minnesota Duluth, Duluth, MN 55812, USA. 3Department of
Chemistry and Biochemistry, Rowan University, Glassboro, NJ 08028, USA. 4Department of Biomedical Sciences,
Cooper Medical School of Rowan University, Camden, NJ 08103, USA. 5Department of Pharmacy Practice and
Pharmaceutical Sciences, University of Minnesota, Duluth, MN 55812, USA. *email: vmereddy@d.umn.edu
Scientific Reports |

(2020) 10:17969

| https://doi.org/10.1038/s41598-020-74572-1

1
Vol.:(0123456789)

www.nature.com/scientificreports/

Figure 1.  Structural design of N-phenylindazolyl diarylureas as potential anticancer agents.

Figure 2.  (A) Synthesis of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate for use in coupling with
synthesized (B) para-ureido carboxylic acids 7a–7k. (C) Synthesis of N-phenylindazole diarylureas 8a–k.

Results

Synthesis of N-phenylindazolyl diarylureas was initiated by utilizing commercially available starting material methyl 1H-indazole-3-carboxylate 1, which was first treated with 4-fluoronitrobenzene 2. The reaction
underwent substitution under basic conditions to provide the corresponding methyl 1-(4-nitrophenyl)-1H-indazole-3-carboxylate 3. The nitro group in 3 was reduced in the presence of Pd/C and ammonium formate to
the corresponding amine 4 (Fig. 2A). Separately, p-aminobenzoic acid 5 was reacted with various isocyanates
6a–k to obtain the corresponding 4-(3-phenylureido)benzoic acids 7a–k (Fig. 2B). Condensation of amine 4
under peptide coupling conditions with diphenylurea benzoic acids 7a–k provided the corresponding indazole
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Compound

4T1

GL261-luc2

MDA-MB-231

MIAPaCa-2

WiDr

8a

1.3 ± 0.4

1.9 ± 0.4

4.8 ± 2.9

14.3 ± 6.8

0.7 ± 0.3

8b

1.5 ± 0.3

1.5 ± 0.4

1.6 ± 0.2

20.7 ± 3.1

2.2 ± 0.8

8c

0.9 ± 0.3

1.4 ± 0.1

1.1 ± 0.2

11.1 ± 5.2

6.7 ± 0.1

8d

2.3 ± 0.5

3.9 ± 0.5

2.5 ± 0.5

4.7 ± 0.9

5.4 ± 1.1

8e

> 50

> 50

> 50

> 50

> 50

8f

3.0 ± 1.0

3.2 ± 1.2

4.6 ± 1.0

5.6 ± 0.6

2.0 ± 0.7

8g

1.9 ± 0.5

1.8 ± 0.1

5.7 ± 0.8

4.5 ± 0.5

2.7 ± 0.5

8h

1.5 ± 0.2

1.8 ± 0.4

2.4 ± 0.3

6.1 ± 0.4

4.0 ± 1.4

8i

4.6 ± 2.1

1.8 ± 0.4

1.7 ± 0.8

4.1 ± 1.4

3.7 ± 1.8

8j

> 50

> 50

> 50

> 50

> 50

8k

6.1 ± 0.3

4.3 ± 0.5

31.0 ± 6.5

5.6 ± 0.5

0.7 ± 0.1

9

> 50

> 50

> 50

> 50

> 50

10

3.9 ± 0.2

1.5 ± 0.4

1.7 ± 0.5

3.8 ± 0.8

1.4 ± 0.1

11

6.8 ± 0.6

1.4 ± 0.9

1.7 ± 0.8

9.2 ± 1.9

7.9 ± 0.3

Table 1.  MTT IC50 (µM) values of compounds 8a–k and 9–11 in 4T1, GL261-luc2, MDA-MB-231
MIAPaCa-2, and WiDr cell lines. Average ± SEM of a minimum three separate experiments.

Figure 3.  Hydrolysis of 8i to generate acid 9 and corresponding amido-amines 10 and 11 with increased
solubility and potential for enhanced stability.
diphenylureas 8a–k (Fig. 2C). Detailed synthetic protocols and spectral characterization can be found in the
supplemental information.
N-phenylindazole diarylureas 8a–k were then evaluated for their effects on cell viability utilizing
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay on aggressive and difficult to treat
cancer cell lines including murine metastatic breast cancer 4T1, murine glioma GL261-luc2, human triple negative breast cancer MDA-MB-231, human pancreatic cancer MIAPaCa-2, and human colorectal adenocarcinoma
WiDr. These cell lines are all derived from aggressive solid tumors, wherein angiogenesis may play an important
role in both tumor growth and metastasis. Hence, these cell lines offer an appropriate platform to screen candidates containing anti-angiogenesis pharmacophores, including diarylurea template found in 8a–k. Further, these
cell lines represent both human and murine neoplasms; suitable for in vivo models in both clinically relevant
xenograft and syngraft based anticancer efficacy studies. These studies indicated that compounds 8a–k showed
effects on cell viability in various cancer cell lines with I C50 values in the range of 0.7–50 µM concentration
(Table 1). However, due to their poor solubility, we hydrolyzed the ester of one of the lead compounds 8i into the
corresponding carboxylic acid 9 (Fig. 3). Compound 8i was chosen based on its superior effects on cell viability,
and presence of metabolically stable 4-Cl, 3-CF3 phenylurea t emplate18–23. However, the acid derivative 9 did
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Figure 4.  Graphical representation of in vitro cell viability assay dose–response curves of lead candidate
compounds 8i, 10, and 11 in (A) 4T1, (B) GL261-luc2, (C) MDA-MB-231, (D) MIAPaCa-2, and (E) WiDr cell
lines. (F) Note retained biological activity between parent ester compound 8i and amido derivatives 10 and
11. Error bars in (A–E) represent the SEM of six technical replicates across three independent experiments,
with each concentration tested in duplicate for each experiment (n = 6). Error bars in (F)represent the SEM of
the IC50 obtained from the three independent experiments (n = 3), and are derived from values in Table 1. All
compounds were tested at the same concentration range (50–0.39 µM) for relative comparison.
not affect cell viability up to 50 µM concentration (Table 1), and we attributed the lack of biological activity to
decreased cell membrane permeability of more polar carboxylate group. Further, we envisioned that the lipophilic
methyl ester in 8i, although biologically active in vitro, would be metabolically vulnerable to hydrolysis via plasma
esterase activity in in vivo systems, and could result in pharmacologically inactive carboxylic acid 9. In this
regard, we sought to modify the ester group in 8i by introducing stable and solubility-enhancing secondary and
tertiary amido-amine units with retained lipophilic characteristics. We hydrolyzed 8i and coupled the resulting
carboxylic acid 9 with N,N-dimethylethane-1,2-diamine and 1-methyl piperazine to obtain the corresponding
amido-amine derivatives 10 and 11, respectively (Fig. 3). Gratifyingly, compounds 10 and 11 retained similar
biological activity with regard to cell viability when compared to parent compound 8i (Table 1, Fig. 4).
Based on their superior biological activity, we selected parent compound 8i and metabolically stable analog 11
as lead candidates for preliminary in vitro mechanism of action studies. Amino-amide analog 10 also exhibited
similar potency in vitro, but unhindered secondary amide may limit the translational potential when compared
to the sterically hindered and stable tertiary amide of 11 with regards to esterase/amidase hydrolysis under
physiological conditions. Hence, 10 was not subjected for further mechanism studies. Based on the track record
of 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-phenylurea template in providing anti-angiogenesis p
 roperties21,22,
the lead candidates were screened for their ability to inhibit tube length in human umbilical vein endothelial cell
line HUVEC. Tube forming ability of endothelial cell lines is a widely utilized method to evaluate a ngiogenesis24
and hence, compounds 8i and 11 were screened for their ability to inhibit the tube formation of HUVEC in vitro.
We treated HUVEC cells with increasing doses of 8i and 11, once initiation of tube formation took place. Total
tube lengths were measured using Image J software and inhibitory response of compounds was estimated. These
experiments indicated that candidate compound 8i (5 µM) and more potently compound 11 (1 and 5 µM)
inhibited HUVEC tube length in HUVEC cell lines (Fig. 5). Interestingly, at this concentration both compounds
were not toxic to HUVEC cells (IC50 > 25 µM, 12 h; data not shown). Furthermore, we investigated the cytotoxic
response of compound 8i and 11 on HUVEC cells for 24 h, we noted similar response (IC50 > 25 µM, 24 h; data
not shown). Thus, these compounds exhibited inhibitory properties at sub-toxic doses, suggesting the effects on
tube length were not due to the cytotoxic response of these compounds.
To understand the translational potential and general tolerance of these candidate compounds, in vivo systemic toxicity and efficacy studies were performed. For these studies, compounds 8i, 10, and 11 were chosen
based on their superior in vitro potency in the experiments described above. Further, these compounds were
also chosen to evaluate potential effects on in vivo efficacy of varying esterase/amidase vulnerabilities of ester
(8i), secondary amide (10), and tertiary amide (11). Compounds 8i, 10, and 11 were administered once daily,
intraperitoneally (i.p.) at a dosage of 25 mg/Kg for 17 days. Body weights, along with behavior, activity, and
grooming patterns, were measured and observed every day initially, and later at ~ 2–5 days. At the end of the
study mice in treatment groups showed no significant body weight loss and exhibited normal behavior, activity,
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Figure 5.  Compounds 8i and 11 decrease HUVEC tube length in vitro. In vitro tube forming assay, and
quantification of tube length was performed as described under “Materials and methods”. Briefly, HUVEC cells
were seeded on top of matrigel and incubated for 4 h to form tubes following VEGF stimulation. Cells were then
treated with 1 µM and 5 µM of compound 8i and 11 for 12 h. The fold changes were calculated by comparing
the tube length of treated versus non-treated cells. Statistical significance (Kruskal–Wallis one-way ANOVA) of
tube length inhibition by compound 8i and 11 was compared to the non-treated cells. All images were captured
using the same magnification and are representative of 10 fields of view (see scale bar, 250 µm). Bars indicate
Mean + SD of 30 independent tube length measurements (n = 30, ****P < 0.0001).

Figure 6.  Systemic toxicity study in CD-1 mice. Mean body weight changes ± SEM (n = 6) in mice with the once
daily intraperitoneal treatment of compounds 8i, 10, and 11.
and grooming patterns when compared to the control group (Fig. 6). Based on these studies, we deduced that
the candidate compounds are in general well tolerated. However, organ function tests such as liver and kidney,
along with necropsy studies of organ harvest and immunohistochemical analysis of microscopic changes need
to be carried out to fully understand the systemic toxicity of these compounds.
As the lead compounds 8i, 10, and 11 were well tolerated in mice, we next evaluated these compounds for
anticancer efficacy on a colorectal cancer WiDr xenograft model. Colorectal cancer is the third most prevalent
malignancy in terms of new cases and deaths in both men and women and hence, we sought to investigate the
efficacy of candidate compounds in this tumor model. Athymic nude mice were injected with 5 × 106 WiDr
cells (suspended in 1:1 mixture of PBS-matrigel) subcutaneously on right flank. Tumors were measured every
2–3 days and treatment was initiated after tumors reached a mean volume of ~ 150 mm3. At this stage, mice
were randomly assigned into groups (n = 6 mice per group) and mice in groups 1–3 were treated with 8i, 10, and
11, respectively, at a dosage of 25 mg/kg, i.p, once daily, for 14 days. Group 4 was administered with clinically
utilized colorectal cancer drug oxaliplatin at a dosage of 10 mg/kg, i.p. once daily and group 5 was injected with
vehicle (10% DMSO, 10% PEG, 40% HS-15 (18.8% w/v in H
 2O), and 40% H
 2O). Tumor volume was recorded
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Figure 7.  Tumor growth inhibition properties of lead compounds 8i, 10, and 11 in WiDr tumor xenograft
model. Data represents the mean + SEM (n = 6) of (A) tumor volumes per day of treatment and (B) end-point
tumor weights. Two-factor anova statistical analysis was utilized to compare tumor growth between treated
groups, vehicle control, and positive control group oxaliplatin (*P < 0.05).

every 2–3 days, and starting on day-12, compound 11 showed statistically significant reduction of tumor with
(P < 0.05) compared to control group (Fig. 7A). Based on the tumor volume, compound 11 exhibited 47% and
39% tumor growth inhibition compared to control and oxaliplatin treatment groups, respectively. At the end
of the study, mice were euthanized, and the tumors were resected and weighed. In this case also, compound 11
showed significant reduction of tumor (P < 0.05) compared to the control group, which accounted for 43% and
38% of tumor growth inhibition compared control and oxaliplatin treatment groups, respectively (Fig. 7B). In
support of our working hypothesis regarding the in vivo lability of methyl ester, we did not see any significant
reduction of tumors with compounds 8i. The N,N-dimethyl ethylene amide 10 exhibited slightly enhanced tumor
growth inhibition properties, but lack of statistical significant efficacy may be attributed to insufficient metabolic
stability of secondary amide when compared to the tertiary piperazine amide 11. Additionally, for the duration of
the experiment, body weight changes were observed in a similar fashion to that of systemic toxicity study (Fig. 6)
to assess general tolerability of candidate compounds in tumor bearing mice. We observed normal body weight
gains indicating that compounds were well tolerated in a treatment setting (data not shown).
To further explore the potential of its use as an anticancer agent, we evaluated the tumor growth inhibition
effects of compound 11 in a highly aggressive stage IV breast cancer 4T1 mouse tumor model that recapitulates
human cancers and can be studied in a non-genetically modified syngraft setting. 5 × 104 4T1 cells (suspended
in 1:1 mixture of PBS-matrigel) were inoculated subcutaneously into the right flank of female BALB/c mice,
and treatment was initiated the following day. Mice were then randomly grouped based on body weight. Group
1 was treated with 11 (25 mg/kg, i.p., once daily), group 2 was administered with clinically used breast cancer
drug doxorubicin (0.5 mg/kg, i.p., three times a week) and group 3 was administered vehicle (10% DMSO, 10%
PEG, 40% HS-15 (18.8%w/v in H2O), and 40% H2O). The treatment was continued for 17 days and at the end of
the study, tumors were resected and weighed where it was found that compound 11 exhibited significant tumor
growth reduction (48%) compared to the control group and doxorubicin (Fig. 8). In a parallel fashion, treatment
tolerability was observed similar to systemic toxicity study where candidate compounds were again well-tolerated
as evidenced by body weight gains, activity, and grooming patterns. Further, it is notable that during optimization of the presented 4T1 tumor model, we had administered doxorubicin at higher concentrations (2–4 mg/kg)
which resulted in intolerable levels of tumor ulcerations; disqualifying higher dosing strategies to be performed
in the present 4T1 syngraft study. In fact, extensive internalization of tumors along with substantial ulcerations
in the study limited tumor volume measurements and for that reason, end-point tumor masses were used as the
reporter of treatment efficacy (Fig. 8).

Discussion

The tumor microenvironment is highly hetereogenous, comprised of numerous tissue types including epithelial
cancer cells, stromal cells, immune cells and endothelial cells. Endothelial cells, in particular, play a vital role in
angiogenesis for the supply of nutrients and oxygen throughout the rapidly dividing tumor25. Hence, numerous
attempts have been made to develop angiogenesis inhibitors—with effective agents targeting various endothelial
growth factors and receptors26. In this regard, we have designed and synthesized a novel class of N-phenylindazole
containing diarylureas as potential antiangiogenic anticancer agents (Figs. 2, 3). Due to the structural similarity of
our candidate compounds with other diphenylurea containing clinical angiogenesis inhibitors such as sorafenib
and regorafenib, we explored the potential of candidate compounds 8i and 11 to inhibit the tube forming ability
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Figure 8.  Anticancer efficacy of lead compound 11 and doxorubicin (Dox) in 4T1 tumor syngraft model. Twofactor anova statistical analysis was utilized to compare tumor growth between treated groups and the vehicle
control (*P < 0.05).

of endothelial cells in a widely employed in vitro model of HUVEC cells. The tube formation assay is a widely
used model to study angiogenesis24. This assay evaluates the capability of endothelial cells to divide and migrate in
response to angiogenic signals, and test compounds can be assessed for their inhibitory effects on these processes.
Specifically, the in vitro HUVEC model employs angiogenic vascular endothelial growth factor (VEGF) to induce
and differentiate endothelial cells to form tube-like structures on a supporting matrix. Hence, alterations in the
tube forming ability of these cells may indicate dysfunction in VEGF stimulatory pathways. Here, we illustrated
that the lead candidate compounds reduced the tube length of HUVEC cells at non-toxic concentrations and
hence, may be working through inhibition of angiogenesis and related processes (Fig. 5). Nonetheless, additional
in vitro and in vivo experiments are needed to fully evaluate the molecular mechanisms of the candidate compounds. Furthermore, the tube length effects of candidate compounds in HUVEC cells may be independent of the
mechanism of cancer cell death in vitro (Table 1) as serum and nutrient rich mono-cultures are not dependent on
endothelial cell growth or VEGF stimulated processes for proliferation. Additionally, mechanism of compound
induced cell death (apoptosis or other means) in in vivo systems where 3D-heterogenous cell types interact to
promote tumor growth is also likely to be different than either in vitro HUVEC or cancer cell lines. Hence, it is
likely that the candidate compounds are acting via pleiotropic mechanisms of action to elicit their anticancer
properties in vitro and in vivo. In fact, diarylurea containing antiangiogenic agents have been found to exhibit
potency across numerous growth stimulatory kinases18–23. In particular, numerous mechanisms of cell death have
been reported for both regorafenib and sorafenib ranging from apoptotsis, necrosis, ferroptosis, autophagy, and
others; involving numerous reported downstream signaling p
 athways27–34. Specifically, it has been reported that
the diphenyl urea template targets numerous growth stimulatory pathways including RAS-RAF/MEK-ERK along
with the PI3K-mTOR axis to provide its anticancer a ctivity35. Additionally, these compounds have been shown
to target platelet derived growth factors and receptors and epidermal growth factors and receptors; expanding
on the hypothesized VEGF/R mechanisms35. Finally, the diphenyl urea template has been utilized in developing HDAC inhibitors, Aurora kinase inhibitors, and also as DNA-directing alkylating a gents35. Based on these
reports, we believe that our candidate compounds may also exhibit pleotropic mechanisms of action in inhibiting cell viability in vitro and tumor growth inhibition in vivo with a combination of cytotoxic and static effects
depending on the tissue type. Nonetheless, in the present study we have designed, synthesized, and evaluated
a new-class of anticancer agents that exhibit potent effects on cancer cell viability in vitro and have illustrated
significant tumor growth inhibition activity in two aggressive solid tumor models of colorectal and breast cancer.

Conclusion

In conclusion, we have synthesized novel diphenyl indazole containing diarylurea compounds as potential
anticancer agents for difficult to treat solid tumors. The synthesized compounds were evaluated against various cancer cell lines including murine metastatic breast cancer 4T1, murine glioma GL261-luc2, human triple
negative breast cancer MDA-MB-231, human pancreatic cancer MIAPaCa-2, and human colorectal adenocarcinoma WiDr. Several of the tested candidates inhibited the cell viability in low micromolar concentrations.
Based on these studies, three candidate compounds 8i, 10, and 11 were selected and further evaluated in vivo
in colorectal adenocarcinoma WiDr xenograft model. These studies indicated that candidate 11 was superior in
arresting tumor growth compared to 8i and 10. The lead candidate 11 was also evaluated for its in vivo efficacy
in aggressive stage IV breast cancer 4T1 syngraft model, where it significantly reduced the tumor growth. Since
diarylurea based drug candidates are known to exhibit antiangiogenic properties, we further studied candidate
compounds 8i and 11 for their preliminary in vitro mechanism of action. These studies indicated that candidate
compounds reduced tube length in endothelial HUVEC cells at sub-toxic concentrations. Further structure
activity relationship studies are required to synthesize and identify a more potent lead compound that can completely suppress the tumor growth, wherein detailed mechanism of action studies can be carried out. However,
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the studies described in the manuscript provide a novel indazole diarylurea structural template which can be
further developed for anticancer applications.

Materials and methods

Cell lines and culture conditions. Human Umbilical Vein Endothelial Cells (HUVEC) were procured
from ATCC and grown in complete Vascular Cell Basal Medium supplemented with Endothelial Cell Growth
Kit-VEGF (ATCC). 4T1 cells (ATCC) were grown in RPMI-1640 (corning) supplemented with 10% fetal bovine
serum (FBS) and penicillin–streptomycin (50 U/ml, 50 µg/ml). GL261-luc2 cells (Perkin Elmer) were grown in
DMEM medium (corning) supplemented with FBS (10%), and penicillin–streptomycin (50 U/ml, 50 µg/ml)
with Geneticin (50 µg/ml) as selection marker. MCF7 cells (ATCC) were grown in α-MEM with FBS (5%), nonessential amino acids (0.1 mM), insulin (10 µg/mL), sodium pyruvate (1 mM), epidermal growth factor (100 ng/
mL), hydrocortisone (10 µg/mL), HEPES (10 mM), and penicillin–streptomycin (50U/ml, 50 µg/ml). MDAMB-231 cells (ATCC) were grown in DMEM medium supplemented with FBS (10%) and penicillin–streptomycin (50 U/ml, 50 µg/ml). MIAPaCa-2 cells (ATCC) were grown in DMEM medium supplemented with FBS
(10%), horse serum (2.5%) and penicillin–streptomycin (50 U/ml, 50 µg/ml). WiDr cells (ATCC) were cultured
in MEM media supplemented with FBS (10%) and penicillin–streptomycin (50 U/ml, 50 µg/ml).
MTT based cell viability assay.

Cellular viability in the presence of test compounds in 4T1, GL261-luc2,
MDA-MB-231, MIAPaCa-2, and WiDr cancer cells was determined using MTT (3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide) assay as previously described by u
 s36. Dose response curves in Fig. 4 were generated using GraphPad Prism 7.04, and were analyzed by means of non-linear regression using a non-constrained/
non-normalized fit model and were parameterized by the log(concentration inhibitor) against response, where
the response represented the percent cell survival when compared to untreated cells. IC50 values were extrapolated from the Prism 7.04 model fit, and represent the concentration of compound resulting in 50% cell survival
between %survival-maximum and %survival-minimum of the resulting logarithmic fit curve. All compounds
were tested at the same concentrations (50–0.39 µM), where resulting I C50 values were compared.

In vitro HUVEC tube‑forming assay. In vitro tube formation assay measures the ability of HUVEC cells
to form capillary-like structures (called tubes) once plated on extracellular matrix support. The endothelial cells
attach and generate mechanical forces on the surrounding extracellular support matrix to create tracks or guidance pathways that facilitate cellular migration. The resulting cords of cells will eventually form hollow lumens.
The experiments were performed exactly described by manufacturer’s protocol. Briefly, first one layer of extracellular matrix was made by adding 50 μL/well of matrigel in 96 well plates. The plate was incubated for 45 min
at 37 °C. The HUVEC cells (2700 cells/ well) were seeded on top of matrigel and incubated for 4 h to form tubes
upon stimulation with VEGF supplement. After 4 h the plate was investigated for tube formation. Once tube
was formed, cells were treated with 1 µM and 5 µM of compound 8i and 11 for 12 h. After incubation, cells were
stained with Calcein AM, and image was captured. The tube length was measured using Image J software. Briefly,
the Image J software program was opened, and then the file to measure the tube length was selected. The tube
length was measured using “draw line” icon. The line was drawn on top of tube, next “analyze” icon was selected,
and the length of all drawn lines was measured and summed. The data were expressed as the means ± SD of the
tube length. At least 10 images from each well were captured and analyzed.
Systemic toxicity in CD‑1 mice. CD-1 mice (Charles River) were randomly assigned into groups (n = 6

mice per group) and mice were administered with compounds 8i, 10 and 11 as indicated in the results section.
Body weights were recorded every day initially and followed by 2–5 days for the duration of the study. At the end
of the study, mice were euthanized.

Tumor growth inhibition studies. 5 × 106 WiDr cells were suspended in 100µL (1:1 PBS: Matrigel)
(Corning, cat. no. 356237) and were injected subcutaneously into the right flank of 4-week-old female athymic
nude mice (Crl:NU(NCr)-Foxn1nu, Charles River). Tumor volume was calculated by measuring the diameter of
the long side (a) and the diameter perpendicular (b) where V = ab2/2. Tumors were allowed to grow until a mean
of ~ 150 mm3 was achieved. Mice were then assigned into groups (n = 6 per group). Tumors were measured every
two or three days. Groups were assigned as follows: compound 8i (25 mg/kg, ip, qd), compound 10 (25 mg/kg,
ip, qd), compound 11 (25 mg/kg, ip, qd), oxaliplatin (10 mg/kg, ip, qd), and vehicle (10% DMSO, 10% PEG, 40%
HS-15 (18.8% w/v in H2O), and 40% H2O. Intravenous oxaliplatin was not employed to avoid possible tail necrosis in line with our IACUC protocol and as also performed in several literature r eports37–39. Additionally, since
our lead candidate compounds were administered intraperitoneally, we envisioned to administer oxaliplatin also
in a similar fashion. The study ended after 14 days or when tumors surpassed acceptable IACUC standards. At
the completion of the study tumors were resected and weighed.
5 × 104 4T1 cells were suspended in 100 µL (1:1 PBS: Matrigel) and were injected subcutaneously into the
right flank of 4-week-old female BALB/c (BALB/cAnNCrl, Charles River). The following day, mice were randomly assigned into various groups (n = 8 mice per group) and the treatment was initiated. The compounds were
administrated once daily, intraperitoneally. Group 1 was treated with compound 11 (25 mg/Kg), group 2 was
given doxorubicin (0.5 mg/Kg, three times a week)40, and group 3 was designated as control group and injected
with vehicle. The compounds were solubilized in a mixture of 10% mL DMSO, 10% PEG, 40% HS15 (18.8%
w/v in sterile water) and 40% sterile water. At the completion of the study tumors were resected and weighed.
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Statistical analysis. Statistical analysis was conducted using GraphPad Prism version 7.04. 2-factor

ANOVA was used for in vivo studies. Kruskal–Wallis one-way ANOVA statistical tests were utilized in HUVEC
tube-forming assays. In all cases, a P-value of < 0.05 was considered significant, and replicates are mentioned in
the text and or legends accompanying the figures.

Ethical approval. The systemic toxicity and anticancer efficacy studies were approved and in compliance

with the University of Minnesota’s Institutional Animal Care and Use Committee [Systemic toxicity 161134326A (Fig. 6); WiDr xenograft 1612-34444A (Fig. 7), and 4T1 syngraft 1706-34857A (Fig. 8)]. All studies were
performed in accordance with the relevant guidelines and regulations, and all protocols were approved by the
University of Minnesota.
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